News & Presentations

Umoja Biopharma Announces Resignation of Board Chair Clay B. Siegall
May 11, 2022

Umoja Biopharma, Inc. announced today Clay B. Siegall, Ph.D. agreed to the Company’s request to resign from Umoja’s board of directors, effective immediately.

READ MORE >

Umoja Biopharma Presents Data on its Synthetic Cytokine Receptor Platform at the International Society for Cell and Gene Therapy Annual Meeting 2022
May 4, 2022

SEATTLE, May 4, 2022 – Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with solid and hematologic malignancies, announced today that it will have an oral presentation at the International Society for Cell

READ MORE >

Umoja Biopharma Announces Activation of First ENLIGHTen Phase 1 Trial Site in Study of UB-TT170, a TumorTag that Targets Folate Receptors to Mark Tumors for Clearance by CAR T Cells
May 3, 2022

The Phase 1 clinical trial will evaluate UB-TT170 in osteosarcoma and follows the recent approval of Umoja’s first IND application by the FDA.

READ MORE >

Umoja Biopharma to Present at the American Society of Gene and Cell Therapy 25th Annual Meeting
May 2, 2022

SEATTLE, May 2, 2022 – Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with solid and hematologic malignancies, announced today that it will have an oral presentation and two posters at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, to be held May 16-19, 2022.

READ MORE >

Umoja Biopharma Presents Data on its iPSC-Based Cell Therapy Platform at the American Association for Cancer Research (AACR) Annual Meeting 2022
April 8, 2022

SEATTLE, April 8, 2022 (GLOBE NEWSWIRE) – Umoja Biopharma, Inc., an oncology company leveraging its proprietary integrated technologies to create next-generation off-the-shelf in vivo (VivoVec) and induced pluripotent stem cell (iPSC) based immunotherapies for the treatment of solid tumors and hematologic malignancies, announced today the presentation of data supporting the use of a synthetic cytokine receptor, the Rapamycin Activated Cytokine Receptor (RACR), to derive synthetic innate lymphoid cells, RACR-induced cytotoxic innate lymphoid cells (RACR-iCILs).

READ MORE >

We are led by a world class team that operates on a foundation of respect for the contributions of everyone on the Umoja team.